Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Sep;55(9):1350-9.
doi: 10.1136/gut.2005.076646.

Treating viral hepatitis C: efficacy, side effects, and complications

M P Manns  1 , H Wedemeyer, M Cornberg
Affiliations
Review

Treating viral hepatitis C: efficacy, side effects, and complications

M P Manns et al. Gut. 2006 Sep.

Abstract

The treatment of hepatitis C has dramatically improved over the past decade. Unlike any other chronic viral infection, a significant proportion of patients with chronic hepatitis C can be cured. However, the current standard therapy--pegylated interferon alpha and ribavirin--has its limitations. Limited efficacy in patients with hepatitis C virus (HCV) genotype 1 and the side effect profile will necessitate the development of new therapeutic approaches. This review describes the efficacy and optimisation of the current standard therapy of hepatitis C and its problems in special patient populations. New treatment directions beyond interferon alpha based therapies are on the horizon.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

References

    1. Hoofnagle J H. Course and outcome of hepatitis C. Hepatology 200236(5 suppl 1)S21–S29. - PubMed
    1. Manns M P, Rambusch E G. Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. J Hepatol 199931(suppl 1)39–42. - PubMed
    1. Jaeckel E, Cornberg M, Wedemeyer H.et al Treatment of acute hepatitis C with interferon alfa‐2b. N Engl J Med 20013451452–1457. - PubMed
    1. Santantonio T, Fasano M, Sinisi E.et al Efficacy of a 24‐week course of PEG‐interferon alpha‐2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 200542329–333. - PubMed
    1. Wiegand J, Buggisch P, Boecher W.et al Early monotherapy with pegylated interferon alfa‐2b for acute hepatitis C infection: The HEP‐NET Acute‐HCV‐II Study. Hepatology 200643250–256. - PubMed

Publication types

MeSH terms